Publicaciones (44) Publicaciones de MARÍA ISABEL BLANCAS LÓPEZ-BARAJAS

2024

  1. Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain

    Future Oncology

  2. Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy

    Molecular Cancer, Vol. 23, Núm. 1

  3. HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2531-2540

  4. Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study

    Pharmaceutics, Vol. 16, Núm. 7

  5. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

  6. Retrospective registry of patients with locally advanced/metastatic HR+/HER2− breast cancer treated in clinical practice in Andalusia

    Clinical and Translational Oncology

  7. The Predictive Value of Blood-Derived Exosomal miRNAs as Biomarkers in Breast Cancer: A Systematic Review

    Clinical Breast Cancer

2023

  1. Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2665-2678), 10.1007/s12094-023-03203-8)

    Clinical and Translational Oncology

  2. Discovery of a synthetic taiwaniaquinoid with potent in vitro and in vivo antitumor activity against breast cancer cells

    Biomedicine and Pharmacotherapy, Vol. 168

  3. Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis

    Breast, Vol. 69, pp. 342-348

  4. HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

    Frontiers in Oncology, Vol. 13

  5. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 9, pp. 1029-1041

  6. Oligometástasis en cáncer de mama: estrategias y perspectivas para el control local del tumor primario y de las metástasis

    Revisiones en Cancer, Vol. 37, Núm. 2, pp. 92-97

  7. SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2665-2678

  8. TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression

    International Journal of Biological Sciences, Vol. 19, Núm. 1, pp. 204-224

2022

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 33, Núm. 6, pp. 616-627

  2. Carcinoma localmente avanzado. Hormonoterapia neoadyuvante en cáncer de mama con expresión de receptores hormonales y HER2 negativo

    Revisiones en Cancer, Vol. 36, Núm. 6, pp. 295-303

  3. Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

    Pharmaceutics, Vol. 14, Núm. 3

2021

  1. Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study

    Seminars in Oncology, Vol. 48, Núm. 2, pp. 145-151

  2. Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

    Scientific Reports, Vol. 11, Núm. 1